Time to diagnosis in multiple sclerosis: Epidemiological data from the German Multiple Sclerosis Registry.


Journal

Multiple sclerosis (Houndmills, Basingstoke, England)
ISSN: 1477-0970
Titre abrégé: Mult Scler
Pays: England
ID NLM: 9509185

Informations de publication

Date de publication:
05 2022
Historique:
pubmed: 28 8 2021
medline: 22 4 2022
entrez: 27 8 2021
Statut: ppublish

Résumé

To investigate the time to diagnosis in multiple sclerosis (MS) in Germany. Analysis of real-world registry data from the German Multiple Sclerosis Registry (GMSR) and performing a primary analysis in patients where month-specific registration of the dates of onset and diagnosis was available. As of January 2020, data of a total of 28,658 patients with MS were extracted from the GMSR, with 9836 patients included in the primary analysis. The mean time to diagnosis was shorter following the introduction of the first magnetic resonance imaging (MRI)-based McDonald criteria in 2001. This effect was most pronounced in younger adults below the age of 40 years with relapsing onset multiple sclerosis (ROMS), with a decrease from 1.9 years in 2010 to 0.9 years in 2020, while unchanged in patients aged 40-50 years (1.4 years in 2010 and 1.3 years in 2020). In the limited number of paediatric onset MS patients, the time to diagnosis was longer and did not change (2.9 years). The current sensitive MRI-based diagnostic criteria have likely contributed to an earlier diagnosis of MS in Germany in younger adults aged 18-39 years with ROMS. Whether this translated to earlier initiation of disease-modifying treatment or had a beneficial effect on patient outcomes remains to be demonstrated.

Identifiants

pubmed: 34449299
doi: 10.1177/13524585211039753
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

865-871

Auteurs

Stefan J Blaschke (SJ)

Department of Neurology, Faculty of Medicine, University Hospital of Cologne, Cologne, Germany.

David Ellenberger (D)

MS Forschungs- und Projektentwicklungs-gGmbH (MSFP), German MS Register by the German MS Society, Hanover, Germany.

Peter Flachenecker (P)

Neurological Rehabilitation Center Quellenhof, Bad Wildbad, Germany.

Kerstin Hellwig (K)

Katholisches Klinikum Bochum, Department of Neurology, Ruhr University Bochum, Bochum, Germany.

Friedemann Paul (F)

Experimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine and Charité Universitaetsmedizin Berlin, Berlin, Germany.

Dieter Pöhlau (D)

DRK Kamillus Klinik, Asbach, Germany.

Christoph Kleinschnitz (C)

Department of Neurology and Center of Translational and Behavioral Neurosciences (C-TNBS), University Hospital Essen, Essen, Germany.

Paulus S Rommer (PS)

Department of Neurology, Medical University of Vienna, Vienna, Austria.

Maria A Rueger (MA)

Department of Neurology, Faculty of Medicine, University Hospital of Cologne, Cologne, Germany.

Uwe K Zettl (UK)

Neuroimmunological Section, Department of Neurology, University of Rostock, Rostock, Germany.

Alexander Stahmann (A)

MS Forschungs- und Projektentwicklungs-gGmbH (MSFP), German MS Register by the German MS Society, Hanover, Germany.

Clemens Warnke (C)

Department of Neurology, Faculty of Medicine, University Hospital of Cologne, Cologne, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH